Bivamelagon (; developmental code names LB54640, LR-19021) is a small-molecule melanocortin MC4 receptor agonist under development by LG Chem Life Sciences for the treatment of hypothalamic obesity, . Unlike the older drug with the same mechanism of action, setmelanotide, it can be taken orally.First-in-Human Study of Safety, Pharmacodynamics of LB54640, An Oral Melanocortin-4 Receptor Agonist Mirza, Victoria, MD, MPH; Lee, Jisoo, MD; Gwak, Heemin; Yang, Yunjeong; Kim, Mina. Obesity; Silver Spring Vol. 30, (Nov 2022): 145-146. As of 9 Feb 2026, Rhythm Pharmaceuticals has completed phase 2 clinical trials.
References